Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

NOTE’s Year-end Report 2021

Financial performance in Q4 (October-December)• Sales increased by 75% to SEK 814 (466) million. Adjusted for acquisitions and currency effects, growth was 48%.• Operating profit was up by 125% to SEK 87 (38) million. Operating profit includes positive non-recurring items of SEK 5 million.• Operating margin increased by 2.3 percentage points to 10.6% (8.3%), adjusted for non-recurring items, the operating margin was 10.0%.• Profit after tax increased by 115% to SEK 68 (32) million, corresponding to SEK 2.39 (1.12) per share.• Cash flow after investments was negatively impacted by

PowerCell joins European development project on fuel cell technology of the future

To accelerate the company’s long-term technological development, PowerCell Sweden AB has joined the coordinated European development project Camelot.The objective of the project is to produce material for fuel cells of the future. Other project participants include leading research institutions, universities and industrial companies, such as BMW.Camelot brings together participants from several European countries and has received funding from the Fuel Cells and Hydrogen 2 Joint Undertaking, FCH JU, under grant agreement number 875 155. FCH JU Joint Undertaking is, in turn, funded by the

IRRAS Announces First Patients Enrolled in ACTIVE Study, a Comparative Clinical Trial Designed to Confirm IRRAflow’s Efficacy to Traditional Passive Drainage

· Dr. Anders Korshøj from Aarhus University Hospital successfully enrolled the first patients in the ACTIVE (Use of Active Fluid Exchange to Treat Intraventricular Hemorrhage (IVH)) clinical study. · ACTIVE will document the hospital’s use of the IRRAflow system and compare its safety and effectiveness to traditional passive ventricular drainage in 120 patients with intraventricular hemorrhage (IVH).  · The ACTIVE study investigators hypothesize that IRRAflow’s combination of automated irrigation and controlled drainage will prove superior to EVDs by reducing complications, decreasing

Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

Optomed Plc Stock Exchange Release 28 January 2022 at 9.30, Helsinki Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings Optomed Plc (“Optomed” or the “Company”) has received a notification in accordance with the Chapter 9, Section 5 of the Finnish Securities Markets Act (as amended, the “SMA”) from BI Asset Management Fondsmægler-selskab A/S (“BIAM”). According to the notification, the total holdings in Optomed shares and votes held by BIAM has decreased to 4.31 % of all of the registered shares in Optomed on 26 January 2022.   The

Alelion develops additional battery system for electrification of Hiab’s cranes

Alelion Energy Systems has received an initial order for development work, including a number of lithium-ion batteries, in the cranes and construction machinery segment.The order value is approximately MSEK 2 and the order is estimated for delivery in the second half of 2022. The order was placed by Hiab, global manufacturer and market leader in the field. Hiab is part of the Cargotec group. Batteries based on lithium-ion technology are becoming increasingly common in construction equipment and work vehicles, a development which is further confirmed by the extended cooperation with Hiab.

New data on drug metabolism and distribution in the eye

One of the most comprehensive ocular pharmacokinetic studies including metabolism so far provides valuable information for ocular drug development.Severe visual illnesses are increasing in our society, and effective treatments are missing for diseases as age-related macular degeneration, diabetic retinopathy, and glaucoma. Both industry and academia are highly interested to advance ocular drug discovery and development. Ocular pharmacokinetics is a key science in this process, and knowledge of drug metabolism and distribution in the eye is required. However, information on drug-metabolizing

Lippulaiva’s full service offer will expand to include a private medical centre and more necessity based retail

CITYCON OYJ Corporate Press Release 28 January 2022 The range of tenants at Lippulaiva, which will open at the end of March, is increasing with several new additions. Terveystalo, Lindex, Clas Ohlson, Normal and Dosva Decor, a completely new interior design company on the Finnish market, will add to a strong tenant mix in the new urban centre at Espoonlahti. The supply of health services in the Espoonlahti area will be strengthened when Terveystalo, one of the largest private health care companies in Finland, opens a 750 square metre clinic in Lippulaiva. Terveystalo will be

CORRECTION – OXE Marine AB (publ) initiates written procedure to amend and waive certain terms in its up to MSEK 200 bonds

The correction concerns the third paragraph. The final redemption date for the bonds is proposed to be postponed by 24 months and not 30 months, until 15 February 2025, as set out below.OXE Marine AB (publ) (”OXE”) has today initiated a written procedure to amend and to waive certain terms in its up to MSEK 200 (or its equivalent in NOK and EUR) Senior Secured Callable Fixed Rate Bonds with ISIN SE0010831545, SE0010831594 and NO0010815442 (“Bond Terms”). The written procedure is initiated in preparation for the closing of OXE’s acquisition of Diesel Outboards’ and Outdoor Network

2020 Bulkers Ltd. (2020) - Conversion of index-linked charter hire for Bulk Shenzhen

Hamilton, Bermuda, January 28, 2022 2020 Bulkers has converted the index-linked charter for Bulk Shenzhen into fixed rate charter at US$32,378 per day, gross, for the period from February 1, 2022, until December 31, 2022. In addition, the vessel will still earn a premium related to the fuel cost savings from the scrubbers. Following the fixed rate conversions of Bulk Shenzhen and Bulk Shanghai, the Company estimates the six vessels trading on index-linked charters, based on current scrubber economics, will need to earn US$8,800 per vessel per day to cover the Company’s cash breakeven

Invitation: Kemira to publish Financial Statements Bulletin 2021 on February 11, 2022

Kemira Oyj, Press Release, January 28, 2022 at 9.00 am (EET)Invitation: Kemira to publish Financial Statements Bulletin 2021 on February 11, 2022   Kemira Oyj will publish its Financial Statements Bulletin 2021 on Friday, February 11, 2022 around 8.30 am Finnish time (6.30 am UK time). Webcast for analysts, investors, and media will be held on Friday, February 11, 2022, starting at 10.30 am (8.30 am UK time). At the webcast, Kemira’s President and CEO Jari Rosendal and CFO Petri Castrén will present the results. The webcast will be held in English and can be followed at www.kemira.

Grant of Options

Faron Pharmaceuticals Ltd (“Faron” or the “Company”) Grant of Options  Company announcement, January 28, 2022 at 09:00 AM (EET) / 07:00 AM (GMT) / 02:00 AM (EDT) TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, announces that the Board of Faron has granted 100,000 options over ordinary shares in the Company (“Options”) under the Faron 2019 Option Plan to Dr. Marie-

Getinge Year End Report 2021: “Healthy order growth, improved EBITA margin and strong cash flow”

“The organic order intake increased 6.4% in the fourth quarter following growth in all business areas and regions”, says Mattias Perjos, President & CEO at Getinge. “Excluding currency effects, our order bookings are more than 20% larger compared with one year ago.”As expected, Getinge’s net sales declined compared with Q4 2020 which saw large deliveries of ICU ventilators. Demand for products for life supporting ECMO therapy and Sterile Transfer remains strong, while other parts of the operations are demonstrating a stable recovery. In particular, this applies to Surgical Workflows, which

Susanna Tevä appointed CFO of Apetit Plc

Apetit Plc, Stock Exchange Release on 28 January 2022 at 09:00 a.m.Susanna Tevä appointed CFO of Apetit Plc Susanna Tevä M. Sc. (Economics and Business Administration) has been appointed CFO of Apetit Plc. She is responsible for the Group's financing and finance, legal and IT. Tevä will start in her position on 1 August 2022 at the latest. She reports to CEO Esa Mäki and is a member of the corporate management team. Previously Tevä has worked for example as Group Financial Controller of HKScan Plc, Finance Director of Euroports Finland Oy as well as CFO and Deputy Managing Director of

Aiforia's Board of Directors established an Audit Committee and a Remuneration Committee

Aiforia Technologies Plc’s ("Aiforia") Board of Directors has decided to establish an Audit Committee and a Remuneration Committee to prepare matters to be considered by the Board.The duties of the Audit Committee include monitoring the reporting of Aiforia's financials as well as practices related to it and monitoring their compliance with law. In addition, the duties of the Audit Committee include monitoring and assessing the risk management system as well as the supervision, monitoring and selection of the auditor.   Aiforia's Board of Directors elected among themselves Pekka

Year-end Report 2021

January–December 2021 compared with January–December 2020 · Net sales amounted to SEK 18,822m (18,410). The discontinuation of the publication paper operations in the first quarter of 2021 (see page 5) and the divestment of Wood Supply UK in the fourth quarter of 2020 (see page 7) had a negative impact on sales. Excluding these effects, net sales increased by 26%. The increase was primarily attributable to higher selling prices in all product areas. · EBITDA increased 105% to SEK 9,109m (4,440[1]). The change was mainly attributable to higher selling prices in all product areas,

Electrolux Q4 2021 Interim report: Ending a record year with solid execution in Q4

Highlights of the full-year of 2021 · In full-year 2021, strong price execution and attractive product and brand offering resulted in record net sales of SEK 125,631m (115,960), operating income excl. non-recurring items of SEK 7,528m (5,778), and operating margin excl. non-recurring items of 6.0% (5.0). Income for the period excl. non-recurring items was SEK 5,220m (3,988). Highlights of the fourth quarter of 2021 · In the fourth quarter 2021, net sales amounted to SEK 35,372m (33,902) and operating income to SEK 882m (2,498), corresponding to a margin of 2.5% (7.4). ·

Cloetta AB interim report Q4: October – December 2021

Branded sales continued to exceed 2019 levels, driven by strong marketing. Margin-enhancing initiatives brought the Pick & mix business close to breakeven for the full year. The dividend proposal is in line with the pre-pandemic level, supported by a healthy cash flow and strong balance sheet.· Net sales for the quarter increased by 13.4 per cent to SEK 1,662m (1,466) including a negative impact from foreign exchange rates of -0.4 per cent. · Sales of Branded packaged products increased organically by 9.3 per cent during the quarter: 1.9 per cent in October, 14.8 per cent in November and

Electrolux Professional AB year-end report Q4 2021

Fourth quarter, October – December 2021· Net sales amounted to SEK 2,309m (1,935). Sales increased by 19.3%. Organically sales increased by 14.2%. The acquisition of Unified Brands contributed with 5.1%. Last year the quarter was more impacted by the pandemic than this year. · EBITA amounted to SEK 164m (142), including acquisition and integration related costs of SEK –56m, corresponding to a margin of 7.1% (7.3). Underlying  EBITA-margin was 9.5%. · Operating income amounted to SEK 141m (119), corresponding to a margin of 6.1% (6.1). · Operating cash flow after investments

Economic upswing in Gothenburg and a successful year for Platzer

· Rental income increased to SEK 1,201 million (1,142) · Income from property management increased to SEK 759 million (680) · Profit for the period increased to SEK 1,709 million (1,374) · Property portfolio increased to SEK 26,031 million (22,575) · Earnings per share totalled SEK 14.24 (11.40) · Best Q4 net lettings in office market since 2017 · Strong future earning capacity · High occupancy rate in our projects thanks to high demand · Board of Directors proposes a dividend of SEK 2.20 per share (2.10), to be paid in two instalments of SEK 1.10 each Platzer’s

Calliditas Therapeutics Announces Commercial Availability and Initial Sales of TARPEYO™

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced the commercial availability and initial sales of TARPEYO™ (budesonide), the first and only FDA approved treatment for IgA nephropathy, indicated for reduction of proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression, generally considered a urine protein-to-creatinine ratio (UPCR) ≥1.5g/g. IgAN is a rare, progressive autoimmune disease, which has a high unmet need with more than 50% of patients potentially progressing to end-stage renal disease (ESRD).[i]“

Proposals of the Shareholders’ Nomination Board to Neste’s Annual General Meeting

Neste Corporation, Stock Exchange Release, 28 January 2022 at 9 a.m. (EET)The Shareholders' Nomination Board, established by Neste Corporation's Annual General Meeting (AGM) on 4 April 2013, has forwarded to the Board of Directors of the Company its proposals to the 2022 AGM.  Board Members The Nomination Board proposes that Matti Kähkönen shall be re-elected as the Chair of the Board of Directors. In addition, the current members of the Board, John Abbott, Nick Elmslie, Martina Flöel, Jari Rosendal, Johanna Söderström and Marco Wirén are proposed to be re-elected for a further term

H & M Hennes & Mauritz AB Full-year report

Full-year (1 December 2020 – 30 November 2021) · The H&M group’s net sales in local currencies increased by 12 percent in the 2021 financial year. Converted into SEK the group’s net sales increased by 6 percent to SEK 198,967 m (187,031). · Gross profit increased to SEK 105,006 m (93,544). This corresponds to a gross margin of 52.8 percent (50.0). · Profit after financial items increased to SEK 14,300 m (2,052). · The group’s profit after tax increased to SEK 11,010 m (1,243), corresponding to SEK 6.65 (0.75) per share. · Cash flow from operating activities increased to SEK

Proposal of the Shareholders’ Nomination Board for the composition and remuneration of Tokmanni’s Board of Directors

Tokmanni Group Corporation        Stock exchange release        28 January 2022 at 9:00 amThe Shareholders’ Nomination Board of Tokmanni Group Corporation proposes to the Annual General Meeting that the number of the members of the Board of Directors remain the same and will be six. The Nomination Board proposes that the current members of the Board of Directors Seppo Saastamoinen, Harri Sivula, Thérèse Cedercreutz, Juha Blomster, Erkki Järvinen and Ulla Lettijeff will be re-elected. All proposed persons have granted their consent to the position. The information relevant considering

Notice to convene the Annual General Meeting of Wärtsilä Corporation

Wärtsilä Corporation, Stock exchange release, 28 January 2022 at 08:35 AM UTC+2Notice to convene the Annual General Meeting of Wärtsilä Corporation Notice is given to the shareholders of Wärtsilä Corporation of the Annual General Meeting to be held on Thursday 3 March 2022 at 3 p.m. EET at the Company’s headquarters at the address Hiililaiturinkuja 2, 00180 Helsinki, Finland. It is not possible to participate in the meeting in person at the meeting venue. The shareholders of the Company may participate in the meeting and exercise their shareholder rights only by voting in advance and by

There are no items matching the current filter
There are no more items matching the current filter
Back to top